scPharmaceuticals Inc. (SCPH)
| Market Cap | 249.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.91M |
| Shares Out | 35.94M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 168,465 |
| Open | 6.92 |
| Previous Close | 6.87 |
| Day's Range | 6.73 - 7.08 |
| 52-Week Range | 3.68 - 10.38 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16.93 (+144.3%) |
| Earnings Date | Mar 22, 2023 |
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is $16.93, which is an increase of 144.30% from the latest price.
News
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22
Management to host conference call and webcast at 4:30 p.m. ET
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)
BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing pr...
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023
scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made...
What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock
scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?
Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questio...
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO rol...
scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event
BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals Announces Pricing of $50 Million Public Offering
BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock
BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure
scPharmaceuticals to Participate in the Jefferies London Healthcare Conference
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
Why Is scPharmaceuticals (SCPH) Stock in the Spotlight Today?
There were not just one, but two press releases from scPharmaceuticals (NASDAQ: SCPH) this morning. Apparently, the U.S. Food and Drug Administration (FDA) approved Furoscix.
UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
Funds to be used to facilitate U.S. commercial launch of FUROSCIX® Funds to be used to facilitate U.S. commercial launch of FUROSCIX®
scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide
scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX® (furosemide injection) at home Presentations highlight the sign...
scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti...